Investor FAQs | CG Oncology

CG Oncology was founded in September 2010

CG Oncology was originally founded as a California corporation on September 24, 2010 under the name Cold Genesys, Inc. On November 30, 2017, the company reincorporated as a Delaware corporation, and on March 31, 2020, the name was formally changed to CG Oncology, Inc.

400 Spectrum Center Drive

Suite 2040

Irvine, CA 92618

You can view our Board of Directors by visiting the Board of Directors section of our website.

You can view our executive leadership team by visiting the Executive Leadership section of our website.

December 31st.

Ernst & Young LLP

CG Oncology is traded on the NASDAQ Global Select Market under the symbol “CGON”.

CG Oncology went public on January 25, 2024.

Shares can be purchased through a stockbroker of your choice.

CG Oncology does not offer a direct stock purchase plan.

Currently, CG Oncology does not offer a dividend or a dividend reinvestment program.

156944100

Broadridge Corporate Issuer Solutions, LLC

51 Mercedes Way

Edgewood, NY 11717

Please contact our transfer agent, Broadridge Corporate Issuer Solutions, by telephone at (844) 998-0339. Broadridge Corporate Issuer Solutions can look up your records and make any necessary adjustments. There is a fee involved for replacing lost certificates. Information is also available at www.shareholder.broadridge.com/bcis.

To change the address on file for your shareholder account, you can log in to your online profile by navigating to www.investor.broadridge.com. Once on the Account Summary page, select “Address Information” from the Account Information menu.

Quarterly & Annual Reports and other investor materials, when available, can be found in the Financial Information section on the Investor Relations page of our corporate website. Additionally, all SEC filings can also be accessed directly from the SEC at www.sec.gov.

You can view our recent press releases by visiting the Press Release section of our website.

For media inquiries please send an email to sarah.connors@cgoncology.com.

You can view information on our development programs by visiting the Pipeline section of our website.

For investor related questions please send an email to ir@cgoncology.com.

Please visit the Email Alerts section of our Investor Relations site and fill out our web form to be added to the CG Oncology distribution list.

To request additional information, please visit our Contact page.

When was CG Oncology founded?

Where was CG Oncology incorporated?

Where is CG Oncology corporate headquarters?

Who are the members of CG Oncology’s Board of Directors?

Who are the members of CG Oncology’s Executive Leadership Team?

When is CG Oncology’s fiscal year-end?

Who is CG Oncology’s independent registered public accounting firm?

On which exchange is CG Oncology listed and what is the ticker symbol?

When did CG Oncology go public?

How can I purchase shares?

Does CG Oncology have a direct stock purchase plan?

Does CG Oncology pay dividends and have a dividend reinvestment program?

What is CG Oncology’s CUSIP number?

Who is CG Oncology’s transfer agent and how do I contact them?

How can I replace my lost stock certificates?

How do I report a change of mailing address?

How can I get a copy of your Annual Report or any other investor materials such as an Investor Relations kit or 10-K?

Where can I find recent CG Oncology press releases?

Who can I contact if I am a member of the media?

Where can I find more information on CG Oncology’s R&D programs?

How do I contact Investor Relations with a question or request?

How can I sign up to receive CG Oncology’s press releases and other company information?

If I have questions regarding CG Oncology that have not been answered, whom should I contact?